A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.

This bill modifies the Public Health Service Act to simplify the process for reviewing biosimilar drugs, which are generic versions of existing biologic medicines. By removing a specific requirement and renumbering a related clause, the legislation aims to reduce regulatory hurdles for manufacturers seeking approval for these products. The change directly impacts pharmaceutical companies and the FDA, potentially allowing for a more efficient evaluation of biosimilars without altering the fundamental safety standards.